title: Risk of Relapse Among Propensity Score Matched Multiple Sclerosis Patients Receiving Natalizumab or Platform Therapy in the US.
authors.affiliation: Biogen Idec Inc., Weston, MA, USA.
authors.forename: C
authors.initials: C
authors.lastname: Watson
authors.affiliation: Truven Health Analytics, Cambridge, MA, USA.
authors.forename: M M
authors.initials: MM
authors.lastname: Bonafede
authors.affiliation: Truven Health Analytics, Cambridge, MA, USA.
authors.forename: B H
authors.initials: BH
authors.lastname: Johnson